Atara Rises Following Reports of FDA Discrepancies Resulting in Rejection of Cell Therapy

Atara Rises Following Reports of FDA Discrepancies Resulting in Rejection of Cell Therapy

Atara Rises Following Reports of FDA Discrepancies Resulting in Rejection of Cell Therapy